Europe's Lantus market is growing steadily due to increasing Type 2 diabetes cases and strong government-funded healthcare systems. Key drivers include aging populations and lifestyle-related health concerns. Restraints such as strict regulatory pathways and biosimilar approvals are influencing pricing. A major trend is the gradual transition from Lantus to biosimilars and newer insulins. Still, consistent demand and policy support offer opportunities, especially in Eastern Europe. Market consolidation among suppliers continues. Europe’s Lantus market is forecast to grow at a CAGR of 2.5%, with Western European nations driving the bulk of demand due to their early adoption and high diagnosis rates.
TABLE - Europe Source: Company Publications, Primary Interviews, and SR Analysis
Europe 2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
2031
2032
2033
CAGR (2024-2033)
U.K.
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
Germany
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
France
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
XX
Total
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
XXX
TABLE - Europe Lantus Market Size & Forecast By Product Type 2021-2033
Product Type | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Branded Lantus (Sanofi) | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Lantus Biosimilars | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis
TABLE - Europe Lantus Market Size & Forecast By Application 2021-2033
Application | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | CAGR (2024-2033) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Type 1 Diabetes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Type 2 Diabetes | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX | XX |
Total | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX | XXX |
Source: Company Publications, Primary Interviews, and SR Analysis